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1. Introduction 
Endometrial cancer is the most common gynecological cancer in developed countries. 
Endometrial cancer primarily affects postmenopausal women, with a median age at 
diagnosis of 60 years approximately 25% of women are premenopausal at diagnosis and up 
to 5% of these are below the age of 40 years [Orr, 1997]. 
2. Clinico-anatomopathological characteristics 
17 studies covering 10,572 women showed a prevalence of a malignancy within endometrial 
polyps in postmenopausal women about 5.42% compared to 1.70% in premenopausal 
women [Lee, 2010]. Endometrial neoplasia was identified in 214 of 3,946 women with 
endometrial polyps who were postmenopausal compared with 68 of 3,997 premenopausal 
women (relative risk 3.86). There were 4,967 women with symptomatic bleeding and 195 
from them (4.15%) had neoplastic polyps compared with 85 of 3,941 (2.16%) without normal 
bleeding, according to the report (relative risk 1.97). Looking at the increased risks seen with 
postmenopausal status and abnormal bleeding, this did not seem to be additive. Polyp size 
did not appear to be associated with malignancy. Women with hereditary nonpolyposis 
colorectal cancer (HNPCC) syndrome have a markedly increased risk of endometrial cancer 
compared with women in the general population. Among women who are HNPCC 
mutation carriers, the estimated cumulative incidence of endometrial cancer ranges from 
20% to 60% [Morrow, 1991; Goff, 1994]. In terms of histopathology, endometrial cancer can 
be considered as two types: type I, endometrioid, most commonly seen in 80-90% of cases 
and type II, and all other forms nonendometrioide serous. Endometrial carcinoma has three 
architectural degrees, depending on Solid to glandular component rate (for grade 1 is <5% 
and >50% for grade 3). That tipycally will be arised in younger obese women, hyper 
lipidemia, and signs of hyperestrogenism (exogenous or endogenous).  Serous carcinomas 
are high-grade carcinomas. Comprising -1% of endometrial adenocarcinomas, the clear cell 
carcinomas are rare. There is an increasing of them in thinner, older women and show no 
hormonal risk factors. The endometrial carcinomas type I are commonly diagnosed at an 
early stage and have a favorable prognosis, often only surgically treated; recurrences are 
usually local (the most common site is pelvis) and curable very frequently with tumor-
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directed radiotherapy. The carcinomas type II from endometrial are present with metastatic 
disease at diagnosis and carry a poorer prognosis (Soslow 2007). Complex or simple 
hyperplasia could be associated with cellular atypia. We can subdivide them into mild 
atypia (nuclear enlargement and rounding with evenly dispersed chromatin)  or moderate 
atypia (clumped chromatin, larger nuclear size, prominent nucleoli). There is a low 
likelihood of hyperplasia without atypia, either simple or complex (1%, 3%) of progressing 
to carcinoma. In contrast, atypical endometrial hyperplasia is believed to be the direct 
precursor to endometrioid carcinoma [Bokhman, 1983; Soslow, 1997]. An investigation by 
The Gynecologic Oncology Group  found that from19% to 62% of endometrial biopsy. There 
is an association between endometrial hyperplasia and invasive endometrial cancer 
postoperative. (Merisio, 2005) Complex and simple hyperplasia can be treated with only 
progestative therapy, whereas hysterectomy is mandatory for patients with atypical 
hyperplasia. Atypical hyperplasia regresses after treatment with progestational therapy in 
60% to 95% of patients [Randall, 1997]. 
In patients with atypical hyperplasia and the high risk of progression to endometrium 
carcinoma, hysterectomy is the standard treatment. For women who desire a fertility 
preserving therapy should be reserved progestative therapy for six months (Trimble, 2006). 
The risk factors of endometrioid cancer are late menopause, continuous anovulation (e.g., 
polycystic ovarian syndrome), obesity and nulliparity. Additional risk factors may be 
related to estrogenic effects, a high-fat diet, tamoxifen use, early menarche. Endometrioid 
adenocarcinomas frequently show genetic instability, typically found in patients with 
hereditary nonpolyposis colon cancer and mutations (the b-catenin gene is more frequently 
mutated in carcinomas with squamous differentiation).  Serous carcinomas are characterized 
by chromosomal instability and p53 mutations. Clear cell carcinomas have absent reactivity 
for estrogen and progesterone receptors and low immunoreactivity for p53. After an initial 
assessment, necessary treatment of the disease, this depends on its stage of development 
and disease risk (the risk of recurrence and metastasis). 
2.1 Assessment 
Assessment of myometrial invasion is to specify the page, the possible extension to the 
pelvic organs and distance and tumor grade. This evaluation consisted of noninvasive 
preoperative investigations (imaging) and invasive (biopsy curettage). CT scans have poor 
sensitivity and specificity in detecting the depth of myometrial invasion, cervical and 
parametrial involvement, and lymph node metastases [Zerbe, 2000]. MRI appears to be the 
best imaging modality for preoperative assessment of myoinvasion [Kinkel, 2009]. MRI 
presents an overall staging accuracy of 85% [Hricak, 1991]. In addition, whilst more accurate 
than CT, the limitations of MRI in detecting myometrial invasion must be considered 
[Kinkel, 1999]. In one institutional review of endometrial cancer, 30% of tumors were found 
to be at an advanced stage and 24% of women had high-grade tumors [Bandyopadhyay, 
2008]. Another study of 301 women with stage I endometrial cancer reported that the 
negative predictive value of MRI for myometrial invasion was 49.2% [Suh, 2009]. The use of 
PET/ CT is reported in small prospective series to have a high negative predictive value for 
nodal metastases [Frumovitz, 2004; Signorelli, 2009; Picchio, 2010]. Park demonstrated that 
PET/CT had a sensitivity of 69.2%, specificity of 90.3%, positive predictive value of 42.9%, 
and negative predictive value of 96.6 % [Park, 2008]. 
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Endometrial cancer is generally staged according to the International Federation of 
Gynecology and Obstetrics (FIGO) system. Since 1988, the FIGO system has recommended 
surgical staging with systematic pelvic and para-aortic lymphadenectomy. In May 2009, a 
new FIGO staging system was published, but most of studies are based on the old 
classification (Tables 1). Some centers use intraoperative frozen section analysis of the uterus 
based upon histological grade, type and depth of myometrial invasion and appears 
significantly better than MRI scanning in the assessment of myometrial invasion. 
[Furukawa, 2010]. 
 
Stage Involvement 
Stage I Tumor confined to the corpus uteri 
IA No or less than half myometrial invasion 
IB Invasion equal to or more than half of the myometrium 
Stage II Tumor invades cervical stroma, but does not extend beyond the uterus 
Endocervical glandular involvement alone should be considered as stage I 
Stage III Local and/or regional spread of the tumor 
IIIA Tumor invades the serosa of the corpus uteri and/or adnexae†  
IIIB Vaginal and/or parametrial involvement†  
IIIC Metastases to pelvic and/or para-aortic lymph nodes†  
IIIC 1 Positive pelvic nodes 
IIIC 2 Positive para-aortic lymph nodes ± positive pelvic lymph nodes 
Stage IV Tumor invades bladder and/or bowel mucosa, and/or distant metastases 
IVA Tumor invasion of bladder and/or bowel mucosa 
IVB Distant metastases, including intra-abdominal metastases ± inguinal nodes 
*Positive cytology should be reported separately without changing the stage [Pecorelli, 2009]. 
Table 1. FIGO staging of endometrial cancer 
2.2 Risk assessment 
Multiple factors have been identified for relative high risk of recurrence in apparent early-
stage disease: histological subtype, grade 3 histology, myometrial invasion ‡50%, 
lymphovascular space invasion (LVSI), lymph node metastases and tumor diameter >2 cm. 
Stage I can be subdivided into three risk categories [Fiorelli, 2008]: 
Low risk:   stage IA (G1 and G2) with endometrioid type 
Intermediate risk:  stage IA (G3) with endometrioid type 
                                               stage IB (G1 and G2) with endometrioid type 
High risk:   stage IB (G3) with endometrioid type 
                                               all stages with non-endometrioid type 
2.3 Surgical staging 
Full staging endometrial cancer can be performed surgically [Pecorelli, 2009]. In addition to 
data related to uterine tumor, surgical research can provide data about state and pelvic 
lymph lomboaortic by lymphadenectomy. Studies of women undergoing full pelvic 
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lymphadenectomy report rates of occult pelvic lymph node disease ranging from 8 to 28% 
depending on grade and depth of myometrial invasion [Zivanovic, 2009; Lin, 2008]. 
Lymphadenectomy causes significant morbidity in approximately 11% of cases [Nunns, 
2000]. Pelvic MRI and sentinel lymph node evaluation appear equally effective in detecting 
pelvic node metastases although the ability to detect the sentinel node varies significantly 
between studies [Selman, 2008]. Hirahatake reported that para-aortic lymph node 
metastases in 2.5% of stage IA, 8.5% of stage IB, and 15.7% of stage II endometrial cancers 
[Hirahatake, 1997]. Mariani and Tanaka reported a direct correlation between pelvic and 
para-aortic lymph node involvement [Mariani, 2004; Tanaka, 2006]. In a study of 291 
endometrial cancer patients by Goudge 18% were upgraded postoperative [Goudge, 2004]. 
Ben-Shachar reported that tumor was upgraded in 19% of 181 patients with a preoperative 
grade 1 tumor [Ben-Shachar, 2005]. The results of surgical staging also led to adjuvant 
treatment in 12% of patients who were found to have extrauterine disease or other high-risk 
characteristics [Ben-Shachar, 2005]. 
3. Prevention  
Pain was the most common complain in patients with recurrent disease, in the follow-up of 
endometrial cancer patients, followed by vaginal bleeding, general malaise, loss of weight 
and intestinal complaints (Zhang, 2010). The routine use of the Pap smear and systematic 
radiography are not clinically justified in the follow-up of patients with endometrial 
carcinoma (Agboola, 1997; Morice, 2001). In Lynch syndrome, the current gynecologic 
carcinoma screening guidelines include annual endometrial sampling and transvaginal 
ultrasonography beginning at age 30-35 years (178). Primary prevention by using a 
progesterone device in utero, such as the Mirena IUCD is an alternative approach. This 
merits full evaluation (Hitchener, 2006). Prophylactic hysterectomy and bilateral 
salpingoophorectomy should be offered as risk-reducing surgery to women aged 35 years or 
older who do not wish to preserve fertility. Schmeler  et al. reported a retrospective analysis 
with known germ line mutations associated with Lynch syndrome. There were sixty-one 
participants who underwent prophylactic hysterectomy and were compared to over 200 
matched controls with similar mutations that did not have preventive surgery. In 33% of the 
controls was eventually diagnosed the endometrial cancer, with no cases in the prophylactic 
group (Schmeler, 2006). There was detected asymptomatic muscle invasive endometrial 
carcinoma by Pistorius et al, in two of four women who underwent prophylactic 
hysterectomy after requiring surgery for Lynch syndrome related colorectal carcinoma 
(Schmeler, 2006). In 2006, a multiinstitutional, matched case-control study found that 
prophylactic bilateral salpingoophorectomy and hysterectomy preventive strategy in 
women with HNPCC syndrome [Schmeler, 2006]. Most cases of endometrial cancer cannot 
be prevented, but women can take some measures to reduce their risk of developing 
endometrial cancer. Risks might be reduced with using oral contraceptives controlling 
obesity  and controlling diabetes. 
In addition, women who are considering estrogen replacement therapy should talk to their 
doctors to assess their risk of endometrial cancer. Use of combination oral contraceptives 
(birth control pills) decreases the risk of developing endometrial cancer. 
Women who use oral contraceptives at some time have half the risk of developing 
endometrial cancer as women who have never used oral contraceptives. 
www.intechopen.com
 
Prevention and Therapeutic Strategies in Endometrial Cancer 
 
445 
This protection occurs in women who have used oral contraceptives for at least 12 months, 
and continues for at least 10 years after oral contraceptive use. The protection is most 
notable for women who have never been pregnant.  
Edward Giovannucci, M.D., Sc.D., Professor of Nutrition and Epidemiology at the Harvard 
School of Public Health, said coffee is emerging as a protective agent in cancers that are 
linked to obesity, estrogen and insulin. Giovannucci, along with Youjin Je, a doctoral 
candidate in his lab, and colleagues observed cumulative coffee intake in relation to 
endometrial cancer in 67,470 women who enrolled in the Nurses' Health Study. During the 
course of 26 years of follow-up, researchers documented 672 cases of endometrial cancer. 
Drinking more than four cups of coffee per day was linked with a 25 percent reduced risk 
for endometrial cancer. Drinking between two and three cups per day was linked with a 7 
percent reduced risk  [Giovannucci, 2005]. A similar link was seen in decaffeinated coffee, 
where drinking more than two cups per day was linked with a 22 percent reduced risk for 
endometrial cancer. 
Hormone and lifestyle factors explain up to 80% of risk for endometrial cancer. The 
investigators found that women who were normal weight and active had a reduction in risk 
of 73%, compared with inactive women who were overweight (BMI above 25 kg/m2). 
Women who were normal weight but inactive had a 55% lower risk for endometrial cancer 
than inactive women who were overweight. Women who were overweight but active had a 
38% lower risk for endometrial cancer. 
Aspirin has been shown in vitro to inhibit endometrial cancer cell growth through the 
induction of apoptosis in a dose-dependent manner [Arango, 2001].  
Other NSAIDs have also been shown to reduce endometrial cancer cell proliferation and 
induce apoptosis in a dose- and time-dependent manner [Gao, 2004; Li, 2002]. 
African-american women with advanced stage endometrial cancer have lower survival rates 
than white women with the disease even when both groups receive similar treatments, 
according to a study published online September 25, 2006, in the journal Cancer . 
4. Therapeutic strategies  
4.1 Molecularly targeted treatments 
One of the major challenges in endometrial cancer treatment remains the current inability to 
effectively prevent distant metastasis in women with deeply myoinvasive, high-grade or 
biologically aggressive tumors (e.g., serous and clear cell cancers). One potential target in 
serous tumors is HER2 [Konecny, 2009; Villella, 2006; Flemimg, 2003]. The monoclonal 
antibody trastuzumab binds to HER-2 and can reduce growth in cell lines that overexpress 
HER-2. Epidermal growth factor receptor (also known as c-erbB-1). One strategy to tackle 
tumor growth is to target angiogenesis,. The main factor controlling angiogenesis is VEGF. 
The most well known of these is bevacizumab, a monoclonal antibody against VEGF-A. A 
study of single-agent bevacizumab in women with recurrent endometrial cancer 
demonstrated a 15% response rate and a median progression-free survival of 4 months, 
although approximately 36% of women had a progression-free survival of 6 months  
[Konecny, 2009]. 
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A number of other antiangiogenic agents are currently being tested as single agents in Phase 
II trials. These include VEGF–Trap and small-molecule inhibitors of VEGF receptors [Hayes, 
2009; Hayes, 2010]. 
One of the main challenges will be getting the more promising drugs into the clinic. 
Development of these newer drugs is expensive and costs will therefore be high. Whether 
there is a therapeutic role for lymphadenectomy in nonendometrioid tumors remains an 
unanswered. It has been possible to provide clear guidance with respect to the use of 
radiotherapy following the completion and publication of several key trials in this area, and 
treatment is now applied on an individualized patient basis. The investigators found that 
women who were normal weight and active had a reduction in risk of 73%, compared with 
inactive women who were overweight (BMI above 25 kg/m2). Women who were normal 
weight but inactive had a 55% lower risk for endometrial cancer than inactive women who 
were overweight. Women who were overweight but active had a 38% lower risk for 
endometrial cancer. 
4.2 Treatment of localized disease 
In the case of a low-risk disease evolution, with tumor confined to the uterus, non-
aggressive treatment is required, while high-risk disease require evolution untreatment 
multimodal radiochimiotherapy. Treatment of localized disease is mainly surgical and 
consists of a total hysterectomy with bilateral anexectomy as or no lymphadenectomy. The 
problem is the continuing debate and systematic lombo-aortic lymphadenectomy role. 
Lymphadenectomy can be selectively performed in women at highest risk of nodal 
metastases (deeply invasive or high-grade tumors) [Mariani, 2008]. Lymphadenectomy 
causes morbidity in approximately 11% of cases [Nunns, 2000]. In an effort to decrease the 
morbidity that results from lymphadenectomy, the sentinel node approach has been 
successfully employed. If the sentinel node is pathologically negative for metastasis, all 
downstream nodes should also be negative and would not require dissection. This 
technique yielded an overall detection rate of 82%-89% [Niikura, 2004; Delaloye, 2007]. 
Presently the sentinel lymph node biopsy in endometrial cancer is still an investigational 
technique. Studies of women undergoing full pelvic lymphadenectomy report rates of occult 
pelvic lymph node disease ranging from 8 to 28% depending on grade and depth of 
myometrial invasion [Creasman, 1987; Chi, 2008]. At present there is great uncertainty 
regarding what is the optimal adjuvant treatment for localized endometrial cancer. The use 
of adjuvant therapy for endometrial cancer depends on the patient's estimated risk of 
recurrence. Novel techniques for the delivery of radiation, including intensity-modulated 
radiation therapy and tomotherapy are promising technologies to improve the therapeutic 
index for patients receiving combined therapy [Lian, 2008; Salama, 2006; Beriwal, 2006]. A 
number of trials are ongoing to examine novel biologic and target therapies for women with 
endometrial cancer [Konecny, 2008; Kamat, 2007; Wright, 2007; Ozbudak, 2008; Morrison, 
2006]. Systemic treatment for metastatic and relapsed disease may consist of endocrine 
therapy or cytotoxic chemotherapy. 
4.3 Surgical treatment 
The surgical approach for the treatment of endometrial cancer has traditionally been 
laparotomy.  In the last years, the use of minimally invasive techniques is widely accepted 
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by many authors. A recent publication of the GOG LAP2 study has shown similar operative 
outcomes in the minimally invasive surgery group [Walker, 2010]. Authors have reported 
that the economic benefits of laparoscopy [Scribner, 1999]. Laparoscopy seems to provide 
equivalent results in terms of disease-free survival and overall survival compared with 
laparatomy, with further benefit: shorter hospital stay, less use of pain killers, lower rate of 
complications and improved quality of life. An increasing number of studies have shown no 
difference in survival or recurrence between laparoscopy and laparatomy surgery, in early- 
and advanced-stage endometrial cancer [Eltabbakh, 2002; Holub, 2002; Nezhat, 2008]. 
Recent reports have examined robotically assisted hysterectomy in the treatment of 
gynecologic malignancies [Advincula, 2006]. The robotic approach could be a ‘benefit’ in 
obese women. (Boggess, 2008], but access to the high para-aortic area appears to be limited 
compared with the laparoscopic or open surgical approaches [Soliman, 2010]. When surgery 
is not feasible due to medical contraindications (5–10% of patients), external radiation 
therapy with or without intracavitary brachytherapy to the uterus and vagina is suitable for 
individual clinical use [Colombo, 2011]. In three trials women treated with laparoscopic 
hysterectomy were compared with 193 women treated with open surgery and there appears 
to be no significant difference in either disease-free or overall survival [Lin, 2008; Palomba, 
2009]. 
4.4 Surgical treatment in stage I endometrial cancer 
The standard surgical treatment for stage I endometrial cancer is radical hysterectomy and 
bilateral anexectomy with or without lymphadenectomy. In young women with stage IA 
endometrial carcinoma is proposed to preserve fertility, based on the hysteroscopic 
resection of the tumor followed by hormone therapy regimen of megestrol acetate (160 
mg/day) [Mazzon, 2010]. The role of systematic pelvic lymphadenectomy is in current 
debate.  Mariani states that patients with stage I endometrial cancer, excluding stage IA–IB 
G1, systematic lymphadenectomy did not improve disease-free or overall survival [Mariani 
2000]. In the ASTEC randomized trial, women with endometrial cancer confined to the 
uterus and pelvic lymphadenectomy was no evidence of benefit on overall survival or 
recurrence-free survival [Blake, 2009]. The authors recommended that systematic pelvic 
lymphadenectomy cannot be recommended in women with stage I endometrial cancer. 
Lymphadenectomy is highly important for determining a prognosis and in tailoring 
adjuvant therapies. Prognostic factors for para-aortic spread are similar to those for pelvic 
nodal disease and include depth of myometrial invasion and the presence of 
lymphovascular space invasion [Fotopoulou, 2010; Park, 2010; Nomura, 2006]. Many 
authors suggest a lymphadenectomy for intermediate–high risk endometrial cancer (stage 
IA G3 and IB) [Colombo, 2011]. Lymph node sampling did not appear to confer a survival 
benefit in patients with stage IA, grade 1 or 2 tumors, but improved survival in patients 
with grade 3 [Trimble, 1998]. External beam radiation has been shown to reduce the rate of 
locoregional recurrence in intermediate-risk endometrial cancer. The Postoperative 
Radiation Therapy in Endometrial Cancer (PORTEC) trial randomly assigned 715 women 
with endometrial cancer stage IB grade 2-3 tumors or stage IC grade 1-2 tumors who 
underwent surgery treatment to whole pelvic radiotherapy versus no further treatment. 
After 10 years of follow-up there was a reduction in vaginal recurrences from 15 to 4% but 
no difference in survival [Creutzberg, 2000]. Aalders and collaborators published the results 
of 540 women with stage I endometrial cancer that underwent surgical treatment and 
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vaginal brachytherapy and were randomized to whole pelvic radiation versus observation. 
Pelvic control was improved with the addition of radiotherapy, but there were no survival 
differences at 5 years [Aalders, 1980]. Nout publish the results of a randomized clinical trial 
(PORTEC-2) comparing vaginal brachytherapy and external beam radiation in intermediate-
risk patients [Nout, 2010]. This study showed no any difference in overall survival or 
progression-free survival (PFS). The quality of life was better in the vaginal brachytherapy 
treatment. Radiation of patients who underwent hysterectomy with comprehensive 
lymphadenectomy improves local control and disease-free survival, but did not affect 
overall survival. (Keys, 2004) but is associated with appreciable toxicity [Creutzberg, 2000; 
Keys, 2004]. ESMO Guidelines Working Group 2011 recommended in stage IB G1-2 with 
negative prognostic factors pelvic radiotherapy and/or adjunctive chemotherapy could be 
considered [Colombo, 2011]. Endometrial cancer stage I with grade 3 tumors combination 
chemotherapy to pelvic radiotherapy require. Platinum-based chemotherapy can be 
considered in stage I G3 with adverse risk factors (patient age, lymphovascular space 
invasion and high tumor volume) platinum-based adjuvant chemotherapy for early (stage I) 
disease improves PFS and overall survival. Two trials, one Italian and one Japanese in high-
risk patients comparing five courses of cisplatin, doxorubicin and cyclophosphamide with 
external pelvic radiation reported no difference between therapies in terms of PFS or overall 
survival [Maggi, 2006; Susumu, 2008]. Chemotherapy appeared superior to pelvic 
radiotherapy in patients with stage IC, aged >70 years with outer half myometrial invasion, 
with grade 3, or with stage I disease and positive peritoneal cytology [Maggi, 2006]. In a 
Cochrane Collaboration review of adjuvant radiotherapy for stage I, external-beam 
radiotherapy resulted in a 72% reduction in pelvic relapses, a reduction in death in patients 
with multiple high-risk factors (stage IC and grade 3 tumors) did not translate into a 
reduction in distant metastatic [Kong, 2007]. 
4.5 Surgical treatment in stage II endometrial cancer 
Traditionally, the surgical approach consists of radical hysterectomy with bilateral salpingo-
oophorectomy and systematic pelvic lymphadenectomy with or without paraaortic 
lymphadenectomy. In stage II, lymphadenectomy is essential to guide surgical staging and 
adjuvant therapy. Para-aortic dissection should aim to remove the nodes to level of the 
mesenteric artery up to the renal vessels, rather than restricting dissection to the level of the 
inferior mesenteric artery. Large retrospective nonrandomized studies demonstrated that 
women, who have a para-aortic dissection, have improved outcomes, with increased overall 
survival [Chan, 2006; Chan, 2007]. Authors show that women at intermediate or high risk of 
disease recurrence should have pelvic and para-aortic lymphadenectomy and no benefit 
was seen in low-risk patients [Todo, 2010]. ESMO suggests that adjuvant treatment in stage 
II consists of pelvic radiotherapy and vaginal brachytherapy. If prognostic factors (grade 1–2 
tumor, myometrial invasion <50%, LVSI and complete surgical staging) are negative- 
brachytherapy alone. If prognostic factors are negative it is feasible chemotherapy 
with/without radiation [Colombo, 2011]. 
Chemotherapy appeared superior to pelvic radiotherapy in patients with stage II with a 
significantly higher overall survival and progression-free survival and the rate of pelvic 
recurrence was the same (7%). (Susumu, 2008) Platinum-based chemotherapy can be 
considered in this stage. In retrospective series that platinum-based adjuvant chemotherapy 
for stage II disease improves PFS and overall survival [Soliman, 2010]. 
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4.6 Surgical treatment in stage III-IV endometrial cancer 
Maximal surgical debunking is imperative in patients with a good performance status. The 
surgical approach consists of anterior and posterior pelvic exenteration. For distant 
metastatic disease, palliative surgery could be considered in patients with a good 
performance. If positive nodes: radiotherapy. If metastatic disease: chemotherapy–
radiotherapy for palliative treatment [Colombo, 2011]. Traditionally, treatment for women 
with stage III endometrial cancer has relied on radiotherapy while women with stage IV 
disease have been treated with palliative chemotherapy [Ross, 2008; Denschlag, 2007; 
Mariani, 2006].  396 women with stage III or IV disease were randomized to postoperative 
whole abdominal radiation versus chemotherapy with doxorubicin and cisplatin. Patients in 
the chemotherapy group had a statistically significant increased progression-free (42 vs 
38%) and overall survival (53 vs 42%) [Gallion, 2003]. Agents for endometrial cancer appear 
to be doxorubicin and cisplatin. Response rates to single-agent doxorubicin alone are 
generally in the range of 17-25% [Carey, 2006; Gallion, 2003]. Two prospective randomized 
trials have demonstrated a superior response rate to doxorubicin and cisplatin as compared 
with doxorubicin alone, however, with similar survival rates [Thigpen, 1994; Thigpen, 2004, 
Aapro, 2003]. When carboplatin is associated with cisplatin, is reported a response rate of 
greater than 40% [Akram, 2005; Dimopoulos, 2000; Sovak, 2006; Secord, 2007]. Given this 
provocative data, doxorubicin plus paclitaxel was investigated by the GOG (GOG 163) as an 
alternative to doxorubicin and cisplatin for women with advanced or recurrent disease. 
Doxorubicin, cisplatin and paclitaxel demonstrated a significant improvement in response 
rate, progression free and overall survival, but toxicity was much higher with the three drug 
regimen [Fleming, 2004]. The combination with cisplatin and doxorubicin or cisplatin, 
doxorubicin and paclitaxel for women with stage III and IV completely resected endometrial 
cancer appeared equivalent [Alvarez, 2007; Bruzzone, 2004]. Patients with stage IIIC 
underwent adjuvant treatment with paclitaxel and concurrent pelvic radiation therapy. 
Overall survival was 81% at 3 years with a median time to relapse of 19 months [Mangili, 
2006]. In a similar design, Greven and colleagues reported on 46 patients with endometrial 
adenocarcinoma with greater than 50% myometrial invasion, stromal invasion of the cervix, 
or extrauterine disease confined to the pelvis and/or positive peritoneal cytology that 
underwent postoperative adjuvant treatment with pelvic radiation therapy, vaginal 
brachytherapy and concurrent cisplatin and paclitaxel. Survival at 4 years was 85% [Greven, 
2006]. 
4.7 Locoregional recurrence 
Radiation therapy is standard treatment for vaginal recurrence (external beam plus vaginal 
brachytherapy). There is high rates in local control, complete response (CR) and 5-year 
survival is 50%. Surgery is the treatment of choice for pelvic recurrence, or radiation 
therapy, while for regional pelvic recurrences it is radiation therapy, associated if possible 
with chemotherapy. 
The combination of Doxorubicin, Cisplatin, and Paclitaxel was found to produce an 
improvement in progression free survival for patients with recurrent endometrial cancer, 
compared with the two drug combination of Doxorubicin and Cisplatin [Fleming, 2000]. 
When using adjuvant chemotherapy without adjuvant radiation therapy in patients with 
advanced-stage endometrial cancer, 40% of women experienced a pelvic relapse at 3 years 
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[Mundt, 2001]. Five year local control rate of 54%, disease specific survival of 51%, and 
overall survival of 44% has been reported in a group of patients with locoregional 
recurrence who made radiotherapy alone [Sears, 1994]. The tumors tend to become resistant 
to progestational therapy, but may offer a prolonged complete response interval [Fiorica, 
2000]. For first-line chemotherapy combinations regimens are preffered of recurrent 
endometrial cancer. 
4.8 Advanced disease 
There is no agreement on the standard treatment for women with advanced endometrial 
cancer. A combination of optimally debulked, radiotherapy and chemotherapy is 
employed. Metastatic endometrial cancer can be effectively treated with progestational 
agents. Response rates ranged from 40% with grade 1 disease and 0% with Broder's grade 
4 lesions. [Podratz, 1985].  ESMO recommended   hormonal therapy for endometrioid 
histologies only with overall response 25% [Colombo, 2011]. Chemotherapy alone 
determines a response rate of 40%. The most commonly used are compounds, 
antracyclines and taxanes, alone and in combination. Paclitaxel-based combination 
regimens are preffered for first-line chemotherapy of advanced endometrial cancer. The 
consistent response rate was only for paclitaxel>20% [Colombo, 2011]. The paclitaxel-
containing regimens demonstrated a response rate > 60% and a possibly prolonged 
survival. GOG shows that patients with metastatic endometrial carcinoma require pelvic 
irradiation with or without paraaortic irradiation, followed by cisplatin, doxorubicin and 
paclitaxel (Randall, 2006). 
4.9 Papillary serous carcinoma and clear cell carcinoma 
Papillary serous and clear cell carcinoma require total hysterectomy, bilateral 
salpingoophorectomy, pelvic and paraaortic lymphadenectomy, omentectomy, 
appendectomy and peritoneal biopsies. There is more aggressiveness with higher rates of 
metastatic disease and lower 5-year survival rates. The same chemotherapy regimens 
usually used for ovarian cancer could be also used in women with advanced or recurrent 
papillary serous or clear cell uterine cancer. Papillary serous endometrial carcinomas have 
not been considered to be hormone responsive [Colombo, 2011]. 
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